Literature DB >> 620479

Pharmacokinetics of fentanyl as determined by radioimmunoassay.

R Schleimer, E Benjamini, J Eisele, G Henderson.   

Abstract

The pharmacokinetics of fentanyl were determined in human surgical patients using radioimmunoassay. Fentanyl was measured in the serum, cerebrospinal fluid (CSF), and urine of patients receiving 0.1, 0.5, or 1.0 mg/m2 of fentanyl intravenously. The kinetics of the disappearance of fentanyl from the serum were very similar at the three administered doses. At all doses, levels fell rapidly in the first five minutes to approximately 20% of the peak value. Thereafter, serum levels fell more slowly with an observed half-life (t 1/2) of approximately 10 to 20 min. depending on dose. By 2 hr serum levels had stabilized at low values (1, 5, and 8 ng/ml) and continued to decrease very slowly thereafter, with an observed t 1/2 of 1 to 2 hr at the low dose (0.1 mg/m2) and greater than 4 hr at 0.5 and 1.0 mg/m2. The serum elimination curves were dissected and described mathematically in terms of a three-compartment model. Urinary excretion of fentanyl accounted for 15% to 20% of the administered dose. Urinary excretion was very low during the first 2 hr, suggesting that this route of elimination is not important in terminating the actions of fentanyl in man. Fentanyl levels in the CSF of patients given terminating the actions of fentanyl in man. Fentanyl levels in the CSF of patients given the high dose (1 mg/m2) were low, and never exceeded 4 ng/ml. Peak levels of fentanyl in the CSF were not seen until at least 15 min after administration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620479     DOI: 10.1002/cpt1978232188

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Solubility and related physicochemical properties of narcotic analgesics.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

2.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 3.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

4.  Concentration of fentanyl in colostrum after an analgesic dose.

Authors:  P L Steer; C J Biddle; W S Marley; R K Lantz; P L Sulik
Journal:  Can J Anaesth       Date:  1992-03       Impact factor: 5.063

Review 5.  Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

6.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

Review 7.  Clinical pharmacokinetics of fentanyl and its newer derivatives.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

9.  Pharmacodynamics of fentanyl citrate in patients undergoing aortocoronary bypass.

Authors:  Adolph J Koska; Alexander Romagnoli; William G. Kramer
Journal:  Cardiovasc Dis       Date:  1981-09

10.  Opiate analgesia and its antagonism in dental event-related potentials: evidence for placebo antagonism.

Authors:  S H Butler; Y H Colpitts; G J Gagliardi; A C Chen; C R Chapman
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.